MAnagement of Systolic Blood Pressure During Thrombectomy by Endovascular Route for Acute Ischaemic STROKE
Condition(s) studied
Investigational drug(s) / intervention(s)
Blood pressure management of Systolic Blood Pressure to maintain target range +/- 10 mmHg: Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
Study summary
Stroke is the third most common cause of death in New Zealand and is one of the leading causes of long-term disability at all ages. A life-saving clot retrieval procedure can save lives and prevent disability of patients with ischaemic stroke who get to hospital in time. In New Zealand, 90% of clot retrieval procedures are performed under general anaesthesia. Many anaesthetic drugs can affect blood pressure (BP) and blood flow within the brain. Increasing BP during the procedure could provide additional benefits in this devastating disease. A large trial is needed to investigate BP management during clot retrieval.
Eligibility
Primary outcome measure(s)
- Day 90 Modified Rankin Score — 90 days Post Thrombectomy
The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 (no symptoms at all) to 5 (severe disability). A separate category of 6 is usually added for patients who are deceased.
Trial sites (6)
| Facility | City | Region | Status |
|---|---|---|---|
| Royal North Shore Hospital | Sydney | New South Wales | |
| Gold Coast University Hospital | Southport | Queensland | |
| Metro South Hospital and Health Service via the Princess Alexandra Hospital | Woolloongabba | Queensland | |
| Auckland City Hopsital | Auckland | Auckland | |
| Christchurch Hospital | Christchurch | Canterbury | |
| Wellington Regional Hospital | Newton | Wellington Region |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05645861 on ClinicalTrials.gov ↗ ← All trials in Australia